IL2 and type 1 diabetes mellitus: Another consideration is that IL-2-based therapies might not work in subjects who have genetic defects in IL-2R-signaling such as patients with a T1D-susceptibility IL-2RA haplotype (73) or whose Tregs have become IL-2-unresponsive (74).